STOCK TITAN

GLAUKOS (GKOS) SEC Filings, Sep-Dec 2025

GKOS NYSE

Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.

The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.

Rhea-AI Summary

Glaukos Corp (GKOS) director transaction: On 12/09/2025, a director exercised a stock option to acquire 5,000 shares of common stock at an exercise price of $24.69 per share, then sold 5,000 shares of common stock on the same date at a weighted average price of $107.27 per share across multiple trades.

After these transactions, the director beneficially owns 34,905 shares of Glaukos common stock, which includes 2,569 restricted stock units that have not yet vested or been delivered, as well as vested units with deferred delivery. The director also continues to hold 10,000 stock options with an exercise price of $24.69, originally granted in 2016 and already fully vested.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
insider
-
Rhea-AI Summary

Glaukos Corporation insider has filed notice of a planned sale of common stock under Rule 144. The seller plans to sell 5,000 shares of Glaukos common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $536,368.18. The filing notes that 57,434,740 shares of Glaukos common stock were outstanding at the time referenced. The shares to be sold were acquired on 12/09/2025 through an option granted on 06/02/2016, with cash as the form of payment. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Glaukos’ current or prospective operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
other
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) senior executive stock sale disclosed. The company’s Senior Vice President and Chief Financial Officer reported selling 315 shares of common stock on 11/25/2025 at a price of $105 per share. After this transaction, the executive beneficially owns 50,488 shares of GLAUKOS common stock.

The filing notes that these sales were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025, which is a pre-arranged plan designed to allow insiders to sell stock over time according to set instructions. The reported holdings include 13,751 restricted stock units that have not yet vested or been delivered and 167 stock units acquired through the company’s employee stock purchase plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
insider
Rhea-AI Summary

A shareholder of GKOS filed a Form 144 indicating an intent to sell 315 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The shares have an aggregate market value of 33,075.00 based on the information provided, with the sale targeted for 11/25/2025. These 315 shares came from restricted stock that vested on 04/01/2025 and were received as compensation from the issuer on that date. The filing notes that there were 57,434,740 shares outstanding of the same class of common stock, providing context for the size of this planned sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
other
-
Rhea-AI Summary

Glaukos Corp (GKOS) reported an insider stock sale by its President & COO. On 11/18/2025, the executive sold 19,340 shares of Glaukos common stock at a price of $90 per share. After this transaction, the reporting person beneficially owns 92,366 shares, which includes 62,605 restricted stock units that have not yet vested or been delivered. The filing notes that the report is made by a single reporting person and is signed by an attorney-in-fact on the insider’s behalf.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
insider
-
Rhea-AI Summary

Glaukos Corporation (GKOS) reported that an affiliated holder plans to sell 19,340 common shares under Rule 144. The shares will be sold through Fidelity Brokerage Services LLC on or about 11/18/2025 on the NYSE, with an indicated aggregate market value of $1,740,600. The filing notes that 57,434,740 common shares were outstanding. Most of the shares being sold were acquired between March 2023 and April 2024 through restricted stock vesting as compensation, along with a smaller amount purchased through the company’s employee stock purchase plan. The signer represents that they are not aware of undisclosed material adverse information about Glaukos.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
other
Rhea-AI Summary

Glaukos Corporation announced it intends to use an updated investor presentation, furnished as Exhibit 99.1, in meetings with investors and other stakeholders. The materials are provided under Item 7.01 (Regulation FD) and are available on the company’s investor website at investors.glaukos.com.

The company states the information in Item 7.01 and Exhibit 99.1 is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly referenced. The exhibit is dated November 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
current report
-
Rhea-AI Summary

Glaukos Corporation reported Q3 2025 results. Net sales were $133.5 million for the three months ended September 30, 2025, up from $96.7 million a year ago, while net loss narrowed to $16.2 million with basic and diluted net loss per share of $0.28.

Glaucoma products contributed $110.2 million and Corneal Health $23.3 million in the quarter. Gross profit was $104.7 million; operating expenses were $121.1 million, leading to a loss from operations of $16.4 million. Cash and cash equivalents were $98.2 million and short‑term investments $175.5 million at quarter‑end. Total assets were $999.4 million and stockholders’ equity was $769.5 million.

Year to date, net sales reached $364.3 million versus $278.0 million last year, with net loss of $54.0 million. The company closed the Mobius Therapeutics acquisition with $24.5 million consideration and purchased an adjacent Aliso Viejo building for $16.6 million. Accounts receivable rose, driven by iDose TR’s extended payment terms. Shares outstanding were 57,434,740 as of October 29, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
quarterly report
-
Rhea-AI Summary

Glaukos Corporation filed a current report describing how it shared its latest quarterly information with investors. On October 29, 2025, the company issued a press release announcing its financial results for the third quarter ended September 30, 2025, which is furnished as Exhibit 99.1. Glaukos also prepared a Quarterly Summary with supplemental business and financial information for the same period, furnished as Exhibit 99.2 and made available in the Financials & Filings section of its investor relations website. The company notes that these materials are furnished, not filed, under securities laws unless later specifically incorporated by reference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
current report
Rhea-AI Summary

Joseph E. Gilliam, President & COO of Glaukos Corporation (GKOS), reported a transaction on 09/23/2025 where 1,056 shares of common stock were disposed of at $84.69 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations when restricted stock units vested and were delivered (these RSUs were originally granted on March 18, 2021). After the withholding, the reporting person beneficially owns 111,706 shares, of which 62,605 restricted stock units remain unvested and undelivered. The Form 4 is signed by an attorney-in-fact on 09/24/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
insider

FAQ

How many GLAUKOS (GKOS) SEC filings are available on StockTitan?

StockTitan tracks 174 SEC filings for GLAUKOS (GKOS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GLAUKOS (GKOS)?

The most recent SEC filing for GLAUKOS (GKOS) was filed on November 20, 2026.